CNS PHARMACEUTICALS AG

65 articles with CNS PHARMACEUTICALS AG

• CNS Pharmaceuticals Featured in Syndicated Broadcast Covering Recent Announcements for Glioblastoma Multiforme (GBM) Therapy

  11/24/2020

  CNS Pharmaceuticals, Inc. (NASDAQ: CNSP), today announces that it has been featured in a broadcast via NetworkNewsAudio (NNA), a solution that delivers additional visibility, recognition and brand awareness in the investment community via distribution to thousands of syndication points.

• CNS Pharmaceuticals and WPD Pharmaceuticals to Contribute Sponsorship to 2020 SNO Virtual Meeting

  11/19/2020

  CNS Pharmaceuticals, Inc.   (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced its joint sponsorship with WPD Pharmaceuticals for the 2020 Society of NeuroOncology (SNO) Vir

• CNS Pharmaceuticals Announces FDA Filing of IND for its Brain Cancer Drug Berubicin

  11/17/2020

  CNS Pharmaceuticals, Inc.   (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced

• CNS Pharmaceuticals to Discuss Phase 2 Clinical Trial Design to be Submitted for FDA Review in Webcast at 4:30 PM ET Today

  11/12/2020

  The discussion will be moderated by Robert LeBoyer, Managing Director of Equity Research at Ladenburg Thalmann & Co., Inc.

• CNS Pharmaceuticals Announces Adaptive Trial Design For Berubicin Phase 2 Clinical Trial To Be Submitted for FDA Review

  11/9/2020

  CNS to Discuss Potentially Pivotal Phase 2 Trial for Berubicin in Webcast on November 12th; Adaptive Trial Design May Open Opportunity for Expedited Pathway for Development and/or Approval

• CNS Pharmaceuticals Completes Manufacturing of Berubicin for Phase 2 Clinical Trial

  10/29/2020

  CNS' lead drug candidate Berubicin is proposed for the treatment of glioblastoma multiforme ("GBM"), an aggressive form of brain cancer

• CNS Pharmaceuticals Completes U.S. Manufacturing of Berubicin for Phase 2 Clinical Trial

  10/20/2020

  CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), today announced that the Company's U.S. manufacturer, Pharmaceutics International, Inc. ("Pii"), has completed the manufacturing process for Berubicin Drug Product, its lead drug candidate for the treatment of glioblastoma multiforme

• CNS Pharmaceuticals Highlights New Balancing Act Segment on Glioblastoma Airing on Lifetime TV

  10/12/2020

   CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today highlighted a new segment of "Behind the Mystery" focused on glioblastoma from The Balancing Act airing on Li

• CNS Pharmaceuticals Begins Manufacturing of Berubicin in Europe

  10/9/2020

  CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), today announced that the Company's European manufacturer, BSP Pharmaceuticals S.p.A. ("BSP"),

• CNS Pharmaceuticals Achieves Critical Manufacturing Milestone

  10/1/2020

  CNS Pharmaceuticals, Inc., a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, announced that the Company's GMP manufacturer partner NCK A/S, received a Certificate of Analysis for its Active Pharma Ingredient, clearing it for use in the production of Berubicin.

• CNS Pharmaceuticals and Image Analysis Group Partnership

  9/24/2020

  CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the central nervous system, today announced it has selected Image Analysis Group ("IAG") as the image partner for its upcoming Berubicin clinical tria

• CNS Pharmaceuticals to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

  9/17/2020

  CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the central nervous system, today announced that CEO, John Climaco, will present virtually at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on Tuesday

• CNS Pharmaceuticals to Present at the H.C. Wainwright & Co. 22nd Annual Global Investment Conference

  9/11/2020

   CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the central nervous system, today announced that CEO, John Climaco , will present virtually at the H.C. Wainwright & Co. 22 nd Annual Global Inv

• CNS Pharmaceuticals Announces US Drug Manufacturing Milestones - Sep 03, 2020

  9/3/2020

  CNS Pharmaceuticals, Inc., a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the central nervous system, provides an update on progress for the U.S. manufacturing of Berubicin, the Company's lead drug candidate, in preparation for upcoming clinical trials.

• CNS Pharmaceuticals Announces US Drug Manufacturing Milestones

  9/3/2020

  CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the central nervous system, today provides an update on progress for the U.S. manufacturing of Berubicin, the Company’s lead drug candidate, in preparation for upcoming clinical trials. As previously announced, the Company implemented a dual

• CNS Pharmaceuticals Announces Appointment of Dr. Patrick Wen, Director of Center for Neuro-Oncology at Dana-Farber Cancer Institute, to Science Advisory Board

  8/27/2020

  Dr. Wen's appointment bolsters the Company's neuro-oncology expertise in preparation for upcoming clinical trials of Berubicin in glioblastoma

• CNS Provides FDA Update on IND Filing

  8/25/2020

  CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today provided an update on th

• CNS Pharmaceuticals Engages CRO For Phase 2 Berubicin Clinical Trials

  8/20/2020

  CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announ

• CNS Pharmaceuticals to Provide Second Quarter 2020 Business Update on Thursday, August 13, 2020

  8/11/2020

  CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biotechnology company specializing in the development of novel treatments for brain tumors, today announced that CEO, John M. Climaco, will be issuing a shareholder webinar on August 13th, 2020 at 4:30pm ET

• CNS Pharmaceuticals Recognizes Glioblastoma Awareness Day

  7/22/2020

   CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today recognizes Glioblastoma (GBM) Awareness Day.